Immune Peptide Research Protocol

These peptides modulate immunity through distinct pathways. Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide that enhances T-cell maturation, dendritic cell activation, and Toll-like receptor signaling — it is FDA-approved in over 30 countries for hepatitis B and as an immune adjuvant. Thymalin is a thymic extract containing multiple bioactive peptides that restore thymic function and normalize T-cell subpopulations, with decades of clinical research from the Khavinson laboratory. KPV is a C-terminal tripeptide of alpha-MSH with potent anti-inflammatory activity via NF-kB inhibition and IL-10 upregulation.

Choose compounds based on the specific research question. For T-cell function and adaptive immunity research, Thymosin Alpha-1 is the most extensively studied. For thymic regeneration and age-related immune decline, Thymalin has the strongest preclinical and clinical evidence. For inflammatory modulation and mucosal immunity, KPV is most relevant. Combinations can be studied, but single-compound protocols provide cleaner data.

Published research doses: Thymosin Alpha-1 at 1.6 mg subcutaneously, administered twice weekly (this matches the approved Zadaxin dosing regimen). Thymalin at 5-10 mg daily for 5-10 day courses, with rest periods between courses (Khavinson protocol). KPV at 200-500 mcg subcutaneously daily, or 500 mcg-1 mg orally for gut-targeted research.

If possible, obtain baseline blood work before beginning the protocol. Relevant markers include complete blood count with differential (CBC/diff), lymphocyte subsets (CD4/CD8 ratio), immunoglobulin levels (IgG, IgA, IgM), and inflammatory markers (CRP, ESR, IL-6). At minimum, document baseline health status, any recurrent infections, and subjective well-being.

Follow the Subcutaneous Injection Technique Protocol for Ta1 and Thymalin. Standard injection site is the abdominal subcutaneous tissue. For KPV, subcutaneous injection or oral administration (capsule) depending on research target — subcutaneous for systemic, oral for GI-focused research. Use separate syringes for each compound.

Immune peptides often follow cycling protocols rather than continuous administration. Ta1: twice weekly for 4-12 weeks, then reassess. Thymalin: daily for 5-10 days, then 4-6 month rest before repeating. KPV: daily for 4-8 weeks, then 2-4 week washout. Document exact start and end dates for each cycle.

Track outcomes at regular intervals throughout the protocol. Weekly subjective assessments (energy, well-being, infection frequency). If baseline blood work was obtained, repeat relevant panels at the midpoint and end of the protocol. Compile all data into a structured research report comparing against baseline values.